These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7927807)

  • 61. Construction and characterization of genetically-marked bivalent anti-Shigella dysenteriae 1 and anti-Shigella flexneri Y live vaccine candidates.
    Klee SR; Tzschaschel BD; Singh M; Fält I; Lindberg AA; Timmis KN; Guzmán CA
    Microb Pathog; 1997 Jun; 22(6):363-76. PubMed ID: 9188091
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Local Immune response in rabbits following enteral immunization with live attenuated bacterial Enterobacteriaceae vaccines].
    Dentschev W; Marinova S; Sumerska T; Nenkov P; Koitschev T; Trifonowa A
    Arch Exp Veterinarmed; 1980; 34(1):9-13. PubMed ID: 6998404
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylococci for mucosal subunit vaccine delivery.
    Cano F; Liljeqvist S; Nguyen TN; Samuelson P; Bonnefoy JY; Ståhl S; Robert A
    FEMS Immunol Med Microbiol; 1999 Aug; 25(3):289-98. PubMed ID: 10459584
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Compartmentalization within the common mucosal immune system.
    Moldoveanu Z; Russell MW; Wu HY; Huang WQ; Compans RW; Mestecky J
    Adv Exp Med Biol; 1995; 371A():97-101. PubMed ID: 8526027
    [No Abstract]   [Full Text] [Related]  

  • 65. Technological aspect of the production of live dysentery vaccines for oral administration.
    Denchev V; Nenkov P; Vitanov T; Sumerska T; Marinova S; Vassilev T; Panova I; Bratoeva M; Linde K
    Acta Microbiol Hung; 1991; 38(2):121-6. PubMed ID: 1805499
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.
    Lowell GH; Kaminski RW; Grate S; Hunt RE; Charney C; Zimmer S; Colleton C
    Infect Immun; 1996 May; 64(5):1706-13. PubMed ID: 8613381
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oral immunization of monkeys with polyvalent dysentery vaccine.
    Dhikidze EK; Kavtaradze KN; Krilova RI; Rauss K; Kétyi I; Vertényi A
    Acta Microbiol Acad Sci Hung; 1977; 24(1):7-12. PubMed ID: 412396
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.
    Ledov VA; Golovina ME; Markina AA; Knirel YA; L'vov VL; Kovalchuk AL; Aparin PG
    Vaccine; 2019 Feb; 37(8):1062-1072. PubMed ID: 30670300
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.
    Kotloff KL; Noriega FR; Samandari T; Sztein MB; Losonsky GA; Nataro JP; Picking WD; Barry EM; Levine MM
    Infect Immun; 2000 Mar; 68(3):1034-9. PubMed ID: 10678904
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2.
    Taylor DN; Phillip DF; Zapor M; Trofa A; Van de Verg L; Hartman A; Bendiuk N; Newland JW; Formal SB; Sadoff JC
    Vaccine; 1994 May; 12(6):565-8. PubMed ID: 8036831
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124.
    Li A; Cam PD; Islam D; Minh NB; Huan PT; Rong ZC; Karlsson K; Lindberg G; Lindberg AA
    J Infect; 1994 Jan; 28(1):11-23. PubMed ID: 8163828
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunogenicity of two types of Shigella flexneri 2a O-specific polysaccharide-tetanus toxoid conjugates.
    Polotsky VY; Schneerson R; Bryla D; Robbins JB
    Ann N Y Acad Sci; 1994 Aug; 730():359-60. PubMed ID: 8080210
    [No Abstract]   [Full Text] [Related]  

  • 73. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector.
    Fennelly GJ; Khan SA; Abadi MA; Wild TF; Bloom BR
    J Immunol; 1999 Feb; 162(3):1603-10. PubMed ID: 9973419
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cholera toxin modulates the systemic immune responses against Vibrio cholerae surface antigens after repeated inoculations.
    Fernandez-Miyakawa ME; Brero ML; Mateo NA
    Microbiol Immunol; 2006; 50(8):607-19. PubMed ID: 16924145
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice.
    Yokoyama Y; Harabuchi Y
    Int J Pediatr Otorhinolaryngol; 2002 May; 63(3):235-41. PubMed ID: 11997159
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
    Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
    Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice.
    Pavliakova D; Chu C; Bystricky S; Tolson NW; Shiloach J; Kaufman JB; Bryla DA; Robbins JB; Schneerson R
    Infect Immun; 1999 Oct; 67(10):5526-9. PubMed ID: 10496944
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 79. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
    Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
    Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.
    Jackson RJ; Fujihashi K; Xu-Amano J; Kiyono H; Elson CO; McGhee JR
    Infect Immun; 1993 Oct; 61(10):4272-9. PubMed ID: 8406816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.